Preparing for the potential commercial launch of IGALMI in the at-home setting following the FDA's acceptance of the sNDA. The company has developed a comprehensive launch plan informed by a third-party market assessment highlighting a large total addressable market of up to 86 million annual episodes in the U.S.

Expected impact: Broadens the commercial opportunity for IGALMI by bringing the treatment directly to patients and caregivers in the outpatient setting, potentially driving exponential revenue growth.

The Board of Directors has engaged MTS Health Partners as an external financial advisor to explore and evaluate a wide range of strategic options to maximize shareholder value and support the commercial and development plans for the IGALMI franchise.

Expected impact: Could result in a strategic transaction such as a sale, merger, collaboration, joint venture, licensing deal, or recapitalization to address cash runway constraints.

Focusing clinical development resources strictly on high-potential late-stage programs (specifically BXCL501 for agitation in bipolar, schizophrenia, and Alzheimer's dementia) while reducing overall operating expenses and workforce headcount to extend the cash runway.

Expected impact: Lowers the quarterly cash burn rate, aligning operating expenses with the current development roadmap to preserve remaining cash reserves.